|
Recent news from CGRP Forum
In the last few months, we’ve reported important developments in clinical practice and research including the approval of Nurtec (rimegepant) as the first migraine therapy for acute and preventive treatment, and extensively updated our expert guide to the worldwide regulatory status of anti-CGRP therapies and our summaries of key clinical trials. In addition, we’ve reported from major congresses in the USA and Europe, and reviewed latest real world data with anti-CGRP therapies from a growing range of countries.
Catch up here...
Nurtec (rimegepant) becomes the first migraine therapy for acute and preventive treatment
The US Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant), in a dose of 75 mg every other day, for the preventive treatment of episodic migraine in adults.
Is anti-CGRP therapy approved for your patients?
Take a look at the recent updates on our expert guide to the regulatory status and approved indications for anti-CGRP therapies worldwide.
Clinical trial summaries
Keep up-to-date with the latest clinical trials with easy-to-access summaries of all the key completed and ongoing trials.
Latest real world evidence from the journals and congresses
View the latest real world experiences of anti-CGRP therapies reported by clinicians from Spain and the UK.
“It really is an exciting time to be in headache,” said CGRP Forum Co-Editor, Professor Peter Goadsby. Catch up on all the news from this year’s virtual EAN congress.
Time to rethink chronic migraine classification and other highlights from the American Headache Society congress.
For news of the latest important CGRP publications, click on CGRP in the journals.
For all the other recent migraine news featured on the CGRP Forum, catch up at: News.
If you’d like to contribute your experiences of using anti-CGRP therapies or share CGRP research findings, please get in touch. |
